Use of heterologously expressed human cytochrome P450 1A2 to predict tacrine-fluvoxamine drug interaction in man

Pharmacogenetics

Volumn 8, Issue 2, 1998, Pages 101-108

  Becquemont, Laurent ^a,b,c   Le Bot, Marie A ^b   Riche, Christian ^b   Funck Brentano, Christian ^a   Jaillon, Patrice ^a   Beaune, Philippe ^c  

^a HÔPITAL SAINT ANTOINE   (France)

^b UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Drug interaction; Fluvoxamine; Heterologously expressed human cytochromes P450; Tacrine

Indexed keywords

FLUVOXAMINE; PHENACETIN O DEETHYLASE; RECOMBINANT ENZYME; TACRINE;

ARTICLE; CONTROLLED STUDY; DRUG INTERACTION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; METABOLIC INHIBITION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; YEAST;

EID: 0031970304     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199804000-00002     Document Type: Article

References (38)

1. Becquemont L, Le Bot MA, Riche C, Beaune P. Influence of fluvoxamine on tacrine metabolism in vitro: potential implication for the hepatoxicity in vivo. Fundam Clin Pharmacol 1996; 10:156-157.
2. Becquemont L, Ragueneau I, Le Bot MA, Riche C, Funck-Brentano C, Jaillon P. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 1997; 61:619-627.
3. Belloc C, Baird S, Cosme J, Lecoeur S, Gautier JC, Challine D et al. Human cytochrome P450 expressed in Escherichia coli: production of specific antibodies. Toxicology 1996; 106:207-219.
4. Benfield P, Ward A. Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32:313-334.
5. Benoit GG, Naud CF, Simard MA, Astier AL. Non interference of cytochrome P4501A2 in the cytotoxicity of tacrine using genetically engineered V79 Chinese hamster cells for stable expression of the human or rat isoform and two human hepatocyte cell lines. Biochem Pharmacol 1997; 53:423-427.
6. Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnel ND et al. Warfarin-fluconazole II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996; 24:422-428.
7. Bourrié M, Meunier V, Berger Y, Fabre G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalysed by human liver microsomes. J Pharmacol Exp Ther 1996; 277:321-332.
8. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S. Fluvoxamine is a potent inhibitor of cytochrome P450 1A2. Biochem Pharmacol 1993; 45:1211-1214.
9. Burke MD, Thomson S, Elcombe CR, Halpert J, Haaparanta T, Mayer RT. Ethoxy-, pentoxy-, and benzoyloxy-phenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P450. Biochem Pharmacol 1985; 34:3337-3345.
10. Cornish-Bowden A. Analysis of enzyme kinetic data. Oxford: Oxford Science Publications; 1994.
11. First MR, Schroeder TJ, Weiskittel P, Myre SA, Alexander JW, J PA. Concomitant administration of cyclosporine and ketoconazole in renal transplant recipients. Lancet 1989; 59:1198-1201.
12. Funck-Brentano C, Becquemont L, Leneveu A, Roux A, Jaillon P, Beaune P. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther 1997; 280:730-738.
13. Gautier JC, Lecoeur S, Cosme J, Perret A, Urban P, Beaune P et al. Contribution of human cytochrome P450 to benzo(a)pyrene and benzo(a)pyrene-7,8-dihidrodiol metabolism, as predicted from heterologous expression in yeast. Pharmacogenetics 1996; 6:489-499.
14. Guenguerich FP. Cytochrome P450 enzymes. Am Sci 1993; 81:440-447.
15. Guengerich FP, Turvy CG. Comparison of levels of several human microsomal cytochrome P-450 enzymes and epoxide hydrolase in normal and disease states using immunochemical analysis of surgical liver samples. J Pharmacol Exp Ther 1991; 256: 1189-1194.
16. Härtter S, Wetzel H, Hammes E, Hiemke C. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. Psychopharmacology 1993; 110:302-308.
17. Honig PK, Wortham DC, Zamadi K, Conner DP, Mullin JC, Cantilena LR. Terfenadine-ketoconazole and eletrocardiographic consequences. JAMA 1993; 269:1513-1518.
18. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47:1469-1479.
19. Jensen KG, Loft S, Doehmer J, Poulsen HE. Metabolism of phenacetin in V79 Chinese hamster cell cultures expressing rat liver CYP1A2 compared to isolated rat hepatocytes. Biochem Pharmacol 1993; 45:1171-1173.
20. Jensen KG, Poulsen HE, Doehmer J, Loft S. Kinetics and inhibition by fluvoxamine of phenacetin O-deethylation in V79 cells expressing human CYP1A2. Pharmacol Toxicol 1995; 76:286-288.
21. Kremers P, Beaune P, Cresteil T, De Graeve J, Columelli S, Leroux JP, Gielen JE. Cytochrome P450 monooxygenase activities in human and rat livermicrosomes. Eur J Biochem 1981; 118:599-606.
22. Kukan M, Bezek S, Pool WF, Woolf TF. Metabolic disposition of tacrine in primary suspensions of rat hepatocyte and in single-pass perfused liver: in vitro/in vivo comparisons. Xenobiotica 1994; 24:1107-1117.
23. Kunze KL, Trager WF. Warfarin-fluconazole III. A rational approach to management of a metabolically based drug interaction. Drug Metab Dispos 1996; 24:429-435.
24. Kunze KL, Wienkers LC, Thummel KE, Trager WF. Warfarin-fluconazole I. Inhibition of the human cytochrome P450-dependant metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 1996; 24:414-421.
25. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzales FJ, Tsutsui M. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 1996; 26:681-693.
26. Renaud J-P, Cullin C, Pompon D, Beaune P, Mansuy D. Expression of human liver cytochrome P450 IIIA4 in yeast. A functional model for the hepatic enzyme. Eur J Biochem 1990; 194:889-896.
27. Rochat B, Amey M, Gillet M, Meyer UA, Baumann P. Identification of three cytochrome P450 isoenzymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997; 7:1-10.
28. Rodrigues AD. Use of in vitro human metabolism studies in drug development. An industrial perspective. Biochem Pharmacol 1994; 48:2147-2156.
29. Schoene B, Fleischmann RA, Remmer H, Van Older-Shawsen HF. Determination of drug metabolizing enzymes in needle biopsies of human liver. Eur Clin Pharmacol 1972; 4:65-73.
30. Sewell RB, Brook CW, Mihaly GW, Morgan DJ, Smallwood RA. Intracellular binding is an important determinant of the avid hepatic uptake of the high clearance drug omeprazole. Biochem Pharmacol 1994; 48:846-849.
31. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270:414-423.
32. Smith DA. Species differences in metabolism and pharmacokinetics: are we close to an understanding? Drug Metab Rev 1991; 23:355-373.
33. Spaldin V, Madden S, Pool WF, Woolf TF, Park BK. The effect of enzyme inhibition on the metabolism of tacrine by human liver microsomes. Br J Clin Pharmacol 1994; 38:15-22.
34. Spaldin V, Madden S, Adams DA, Edwards RJ, Davies DS, Park BK. Determination of human hepatic cytochrome P4501A2 activity in vitro. Use of tacrine as an isoenzyme-specific probe. Drug Metab Dispos 1995; 23:929-934.
35. Von Moltke LL, Greenblatt DJ, Court MH, Xiang Duan S, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reputake inhibitor antidepressants. J. Clin Psychopharmacol 1995; 15:125-131.
36. Woolf TF, Pool WF, Bjorge SM, Chang T, Goel OP, Purchase CF et al. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations. Species difference. Drug Metab Dispos 1993; 21:874-882.
37. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992; 22:1-21.
38. Yamazaki H, Inoue K, Turvy CG, Guengerich P, Shimada T. Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metab Dispos 1997; 25:168-174.